MarketBeat · RXRX · November 21, 2026Recursion Pharmaceuticals Reaches FDA Agreement on Key Endpoint for Phase III FAP TrialGet the app for moreExplore stock news, insights and company research.Get the app →Source: MarketBeat ↗